Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anumigilimab safety study in adults with sickle cell disease
2025-521154-42-00Phase 2Authorised
- Sponsor
- CSL Behring
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Anumigilimab with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, Adverse events of special interest and 1 more. Planned start May 2026; status: authorised.
02
Drugs
anumigilimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2025-521154-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521154-42-00.